STUDresearch · Peptide

Hexarelin

Also known as

Examorelin · HEX · EP-23905 · MF-6003 · His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 · Hexareline (misspelling)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Peptide Lots of talk Systemic SubQ Growth hormone axis

Systemic — pituitary GHS-R1a (ghrelin receptor) agonist that triggers whole-body GH/IGF-1 axis pulses plus modest ACTH/cortisol and prolactin spillover.

What people say Hexarelin is a synthetic GH-releasing peptide. Forums discuss a strong pulse and recovery, alongside cortisol, prolactin and fading-response concerns; many accounts also include a GHRH partner. Doses people talk about

Community per-pulse charts50–200 mcg subcutaneously per pulse; one to three daily pulses discussed

About 100 mcg is a frequently quoted middle. Some schedules use one or two pulses, while others describe morning, afternoon and bedtime use; these are not comparative dose-finding results.

Upper community reports200–300 mcg subcutaneously per pulse

Frequency varies between logs. Cortisol/prolactin spillover and desensitization concerns accompany upper-end discussion; the reports do not establish added benefit.

Chronic SC study context1.5 mcg/kg subcutaneously twice daily for 16 weeks

The existing Rahim account includes a 105 mcg twice-daily example for 70 kg and a separate four-week washout. Measured GH-response attenuation and recovery do not validate a community cycle.

IV GH-response study0.5, 1 or 2 mcg/kg intravenously per study exposure

Separate clinical dose-response exposures. The measured GH peak and approximately 55-minute released-GH half-life are not a parent-Hexarelin clearance estimate or SC dose guidance.

Reported amounts and study exposures only. Routes, schedules and outcomes differ; a GH response is not parent-peptide clearance or proof of a body-composition benefit.

Half-life & effect duration

Half-life in the body: IV · ratsAbout 76 minutes
IV · dogsAbout 120 minutes
Human parent peptideNo settled estimate
Felt duration people report: One logA few spaced-out minutes; relaxing on a later occasion
Other accountsRacing mind or trouble sleeping that night

Timing context & sources

How it may feel Reports include flushing, a heavy or tired feeling, appetite changes, brief spaced-out or relaxing sensations, and sometimes energy, racing thoughts or disrupted sleep. Stacks make it hard to separate Hexarelin from the other compounds.

Cycles people discuss Community charts discuss 4–8- or 8–12-week blocks with multi-week breaks, sometimes 4 weeks or roughly equal time off. A separate 16-week SC trial account describes GH-response attenuation and recovery after washout; it does not validate bodybuilding cycles. Timing Morning fasted and bedtime use appear in charts, while some posters move away from night use after sleep disruption. Pre-workout use also appears in a mixed-compound log. Food spacing and these daily slots are reported routines, not an established personal timing rule. Stacks CJC-1295 no-DAC (Mod GRF 1-29) + hexarelin: Classic GHRH + GHRP dual-pulse stack; community often pairs ~100 mcg Mod GRF with ~100–200 mcg hexarelin, 1–3×/day same timing. Access talk 2026 shelves: RUO vials and “strongest GHRP” marketing. Identity/fill risk is the same gray-market problem as other GHRPs. Labs people mention IGF-1 is a weak hex scoreboard. Rahim’s chronic SC schedule found IGF-I largely unchanged even while GH pulses were still happening — 2026 threads that “check if hex works” with a single morning IGF-1 often read a nothing-burger. Watch for Cortisol / ACTH: Dose-related rises at GH-effective doses in human IV studies; community brands hexarelin “dirtier” than Ipamorelin on HPA axis spillover.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Human Hexarelin clearance is not established by the sources checked. The often-cited 55 minutes describes released GH instead.

Separate IV studies report about 76 minutes in rats and 120 minutes in dogs. Neither is a measured human subcutaneous half-life.

Original abstracts reviewed. The human experiment measured GH response after Hexarelin, not parent clearance. The rat mean is 75.9 ± 9.3 minutes; the dog figure is a terminal estimate. No cross-species conversion or claim that no human PK publication exists is made.

Imbimbo et al. (1994): human GH response to Hexarelin (opens in a new tab)Original abstract, GH concentration peak at about 30 minutes, return within 240 minutes and GH half-life about 55 minutes. Actual abstract read via the Europe PMC public core-record API.Abstract only, not full paper. The analyte is GH; this is not a human parent-Hexarelin clearance measurement.
Roumi et al. (2000): Hexarelin disposition in rats (opens in a new tab)Original abstract: IV parent half-life 75.9 ± 9.3 minutes; separate SC bioavailability. Actual abstract read via the Europe PMC public core-record API.Rat experiment, abstract only. The IV half-life is not an estimate for people or a human SC administration.
Roumi et al. (1995): Hexarelin pharmacokinetics in dogs (opens in a new tab)Original abstract: terminal half-life 120 minutes after intravenous Hexarelin in dogs.Original abstract reviewed, not full methods. Species and route prevent transfer to human subcutaneous use.

Felt duration people report

One log reports a few spaced-out minutes; a later injection felt relaxing. Other accounts describe a racing mind or trouble sleeping that night.

These reports do not establish a fixed benefit window. Co-use makes it hard to separate Hexarelin from the rest of the stack.

Elvia1023's 2014 log involves DAC and anabolic steroids; a supplier-related context is visible. Reddit commenters describe stimulation settling after an unspecified time and a sermorelin/Hexarelin sleep problem. Neither measured duration nor prevalence is inferred, and the guide author's dosing advice is not adopted.

Hexarelin and CJC-DAC experience log (opens in a new tab)Elvia1023 post 19, April 25, 2014: a few spaced-out minutes after a pre-workout injection; relaxation after another later injection. Preceding lines disclose concurrent anabolic steroids and DAC.Dated single-person log with multiple compounds and possible commercial affiliation; no isolated effect, universal duration or administration advice adopted.
Hexarelin discussion: actual stimulation and sleep accounts (opens in a new tab)cordex69420 follow-up about warm/energized/racing sensations then settling; probablyfine90's account of a sermorelin/Hexarelin combination and a difficult night.Actual first-person comments reviewed, not the guide-like OP as evidence. Unverified products, co-use and unspecified duration; mechanistic guesses and protocol advice not adopted.

What people say 11

Potency ranking (bro lore): Common forum hierarchy for GH amplitude at comparable doses: Hexarelin ≥ GHRP-2 > GHRP-6 > Ipamorelin; hexarelin often called “strongest GHRP pulse.” forum
Recovery: User logs claim faster training recovery, less DOMS, and better “repair feel” on multi-pulse SC runs—highly confounded by training, sleep, and stacks. forumanecdote
Lean mass / recomp: Anecdotes of fuller look, modest recomp, or improved body comp with diet/training; 16-week clinical SC schedule (1.5 µg/kg BID) did not show significant lean-mass/fat change in that trial design. anecdotetrial
Sleep (mixed): Some report deeper sleep on bedtime pulses; others prefer daytime-only dosing because cortisol/ACTH spillover or restless nights. forum
Appetite: Hunger rise often described as milder than GHRP-6; still present for some users. forum
Stack synergy credit: Many benefit reports attribute results to hexarelin + CJC/Mod GRF or sermorelin dual-pulse stacks rather than hexarelin monotherapy. forum
Strong acute GH pulse: IV human work—GH rises dose-dependently, peaks ~30 min, returns toward baseline within a few hours; ~1 µg/kg near maximal vs 2 µg/kg adding little extra peak. trial
Vs GHRP-2 (head-to-head): Arvat et al.—1 and 2 µg/kg IV GHRP-2 and hexarelin produced similar strong GH responses, both greater than GHRH alone at 1 µg/kg, with similar modest PRL/ACTH/cortisol spillover. trial
GHRH synergy: Low-dose hexarelin + GHRH co-admin produced large GH release with less cortisol impact than higher hexarelin alone in dose-response work—mechanistic basis for the classic “GHRH + GHRP same syringe” stack. trial
Cardiac research interest: Animal/preclinical ischemia-reperfusion, anti-fibrotic, and CD36-related cardiac work drive “heart health” search interest—not a validated self-experimentation protocol. animal
Bone markers (limited): One chronic SC human schedule noted a rise in C-terminal propeptide of type I collagen (formation marker) without clear BMD change in that study window. trial

Doses people talk about 17

Community per-injection (SC): Most common talk band ~50–200 mcg subcutaneous per pulse; ~100 mcg is the frequent “middle” starting/standard pulse. forum
Aggressive / upper community talk: ~200–300 mcg per pulse appears in advanced logs and some vendor-style charts; spillover (cortisol/prolactin) and desensitization risk discussed more at the high end. forum
Total daily community patterns: Classic 2–3 SC pulses/day → rough totals ~200–600 mcg/day depending on per-pulse size; some deliberately use 1–2 pulses/day to limit desensitization. forum
Example community schedules (not standardized): Conservative ~100 mcg 1×/day; standard ~100–200 mcg 1–2×/day; “classic multi-pulse” ~100 mcg 2–3×/day (e.g., AM / afternoon / pre-bed). forum
Timed example often repeated: Three × 100 mcg spaced through the day (e.g., morning, mid-afternoon, night) for ~300 mcg total daily—one common peptides.org-style chart pattern. forum
Weight-scaled clinical band often cited: ~1–2 µg/kg per administration in provocative/SC research contexts; community flat mcg doses (100–200 mcg) are only roughly in that band for typical adult body weights and are not trial-validated flat protocols. trialforum
With GHRH stack (community): Common co-inject talk is hexarelin ~100–200 mcg + Mod GRF 1-29 / CJC-1295 no-DAC ~100 mcg (sometimes 100–200 mcg GHRH) same timing; do not double hexarelin just because stacked. forum
Empty-stomach timing: Strong community preference—often ~1–2+ hours after food and ~20–30+ minutes before carbs/meals, because insulin/glucose is believed to blunt GH pulses (shared GHRP lore). forum
Route note on dose: Human PK/PD peaks in classic papers are largely IV; SC is the forum standard but SC bioavailability is less precisely published than IV—equating community SC mcg to IV trial peaks overstates certainty. trialforum
2026 ceiling talk: 100 mcg remains the middle; 200–300 mcg is framed as more PRL/cortisol, not more GH once you are near the old ~1 µg/kg IV plateau lore. forum
Shorter-block discussion versus Ipamorelin: The 2025–26 charts describe 4–8 weeks on followed by time off or rotation to Ipamorelin, often contrasting this with longer Ipamorelin runs because tachyphylaxis is central to Hexarelin discussion. These are attributed calendars, not an established default or optimal block. forum
Framing: Research and community discussion ranges only—not medical advice, prescriptions, or safety-validated protocols. Gray-market labeled mcg may not equal delivered peptide. forum
Clinical IV dose-response anchors (Imbimbo et al.): Single IV boluses 0.5, 1, and 2 µg/kg; GH Cmax roughly ~27 / ~52 / ~55 ng/mL vs placebo; ED50 for Cmax ~0.50 µg/kg; 2 µg/kg near theoretical max. trial
Low-dose + GHRH synergy (Massoud): Hexarelin 0.125 µg/kg IV + GHRH 1.0 µg/kg produced large GH release with moderate PRL and no cortisol rise in that design—cited as rationale for modest GHRP doses when stacked with GHRH. trial
Chronic SC research anchor (Rahim et al.): Twice-daily subcutaneous hexarelin 1.5 µg/kg body weight for 16 weeks (example: ~105 mcg BID for a 70 kg subject). trial
Ceiling logic from trials: Moving from ~1→2 µg/kg IV added little extra GH peak while spillover hormones still respond—supports community “more is not always more” talk. trial
Clinical IV PRL/cortisol dose-response (Massoud et al.): Hexarelin 0–1.0 µg/kg IV—GH plateau near 1.0 µg/kg (ED50 ~0.48 µg/kg); PRL rises dose-dependently (ED50 ~0.39 µg/kg); cortisol showed a step increase ~40% around 0.5 µg/kg. trial

How it may feel 10

First injections / days 1–7: Community notes describe little classic “stim” feel, facial flush, brief fatigue or a “heavy” sensation, mild appetite change, injection-site sting and possible sleep shifts near bedtime. An inspected multi-agent log reports a few spaced-out minutes and relaxation after another injection; other combination accounts describe warmth, energy, a racing mind or trouble sleeping. These mixed reports do not isolate Hexarelin or establish a typical effect window. forum
Weeks 1–2: Recovery or sleep claims often appear first if they appear at all; possible water retention, joint tightness, or extremity tingling (GH-axis-like). forum
Weeks 2–4: Desensitization talk intensifies—users and some literature frame progressive blunting of GH response with frequent chronic dosing; community checkpoint for whether pulses still “feel worth it.” trialforum
Weeks 4–8: Common window where many end an intensity block or cut pulse frequency; prolactin/cortisol side chatter more common if doses are high. forum
Months 2–3+ continuous: Continuous multi-daily hexarelin less favored than Ipamorelin for long “cruise” style runs; earlier breaks or rotation common. forum
If response fades: Community advice is usually stop / time-off rather than escalate mcg (escalation may worsen spillover and receptor downregulation lore). forum
After multi-week off: Users claim restored pulse strength; clinical data support partial, reversible attenuation after chronic SC use. trialanecdote
Weeks 4–6 fade (2026): Logs describe shrinking “pulse feel” and attribute it to desensitization, while warning against a jump from 100 to 300 mcg. Subjective fading does not measure the GH response or establish an escalation strategy. forum
Rotation discussion: The 2025–26 charts describe switching to Ipamorelin for an off-block instead of stacking a second GHRP. This is community practice, not a recommended substitution or proof that the off-block restores response. forum
Weeks 8–16 (literature anchor): Rahim chronic SC study—AUC of GH response fell significantly by week 4 and further by week 16 on BID hexarelin, with IGF-I largely unchanged; recovery of GH response after 4-week washout. trial

Around the dose 6

Clock: Empty-stomach pulses — AM fasted and/or bedtime. 2026 short-block charts favor 1–2×/day more than old 3×/day blasts. forum
Food-timing discussion: Charts repeat the shared GHRP preference for ~2+ hours after food and a carbohydrate delay. This is community GH-response lore, not a universal administration rule or a timing requirement derived from measured parent clearance. forum
Sleep: Bedtime pulse is argued. Cortisol/ACTH spillover is why some move hex off the night slot. forum
Training context: Older charts frame use as a short intensity block followed by rotation, not a gym-bag pump product. An inspected multi-agent log also describes pre-workout use followed by a few spaced-out minutes. Those are reported patterns, not evidence of an optimal training or administration slot. forum
When the response seems to fade: Logs warn against escalating micrograms when the “pulse feel” fades and discuss time off or a switch to Ipamorelin. These are reported alternatives, not evidence that a particular break or substitution is optimal or safe. forum
Partner: CJC no-DAC / Mod GRF same timing is the dual-path stack; hex + GHRP-2/6 is still called same-receptor pile-on. forum

Cycles people discuss 9

Why cycle talk is heavy: Desensitization / progressive attenuation of GH response with chronic frequent use is better documented for hexarelin than for Ipamorelin and is central to community on/off design. trialforum
Shorter intensity blocks: ~4–8 weeks on is a very common forum recommendation (some charts say 4 weeks on / 4 weeks off for stricter tachyphylaxis control). forum
Medium blocks: ~8–12 weeks on then multi-week off appears in vendor/clinic-style writeups; peptides.org-style material often cites ~12 weeks research-style admin then ~4 weeks break, echoing chronic-trial washout logic. forum
Time-off length (community): Often multi-week off; after longer runs many match ~equal time off or at least ~4 weeks; some prefer longer off than on for hexarelin specifically. forum
Lower-frequency / intermittent strategies: Fewer pulses per day, training-days-only, or 5-on/2-off patterns discussed to slow blunting—none are trial-standardized for body-composition outcomes. forum
Vs Ipamorelin cycle culture: Hexarelin framed as shorter “intensity / pulse power” blocks; Ipamorelin more often run longer as a selective daily GHRP. forum
Re-challenge after break: The existing chronic-SC trial account describes recovery of measured GH response after washout; community logs describe stronger felt pulses after time off. Logs also discourage continuing without a break while escalating the amount. These are different observations and do not establish an optimal re-challenge schedule. trialforum
Stack cycle rule of thumb: When hexarelin is stacked with GHRH, cycle length usually follows hexarelin’s shorter desensitization timeline, not an indefinite CJC cruise. forum
Literature washout (Rahim): After 16 weeks BID SC, GH response to hexarelin was attenuated; 4 weeks off restored AUC GH toward baseline (partial, reversible attenuation). trial

Timing 10

Multi-daily discussion: Community charts use short-action-window logic to describe 2–3 discrete pulses per day rather than weekly-depot or once-weekly use. That is reported scheduling rationale, not a frequency validated by measured human parent-Hexarelin clearance. forum
SC pulse window (community): Usable GH elevation often described as roughly ~1–2 hours after subcutaneous injection (less tightly published than IV). forum
Food / insulin timing: Empty-stomach preference (~2+ hr after meal, wait before large carb meals) is near-universal GHRP community practice to avoid blunted GH release. forum
Bedtime debate: Pre-sleep pulse mimics natural night GH interest for some; others avoid night dosing if cortisol spillover or sleep disruption appears. forum
Oral / nasal PK note: Developmental literature describes oral and intranasal activity (often at higher mcg/kg than SC community doses); oral bioavailability is discussed as limited/variable vs injection—injection remains forum standard. trialforum
GH peak (IV): Plasma GH rises promptly and peaks at about ~30 minutes after IV bolus in classic human PK/PD. trial
Released GH, not Hexarelin clearance: In Imbimbo's human IV experiment, the approximately 55-minute half-life describes plasma growth hormone after Hexarelin; GH peaked around 30 minutes and returned to baseline within 240 minutes. It does not establish the parent peptide's human half-life. trial
Hormone spillover timeline: Modest concurrent rises in prolactin, ACTH, and cortisol accompany GH pulses at effective doses—dose-related in IV studies. trial
Desensitization dynamics: Progressive blunting with chronic administration; human BID SC data show significant AUC GH drop by week 4 and further by week 16, reversible after ~4 weeks off. trial
Downstream IGF-I: Acute GH pulses do not guarantee large IGF-I rises; Rahim chronic SC schedule found IGF-I and IGFBP-3 largely unchanged despite ongoing GH secretagogue exposure—important honesty point for “IGF gains” marketing. trial

Stacks 9

CJC-1295 no-DAC (Mod GRF 1-29) + hexarelin: Classic GHRH + GHRP dual-pulse stack; community often pairs ~100 mcg Mod GRF with ~100–200 mcg hexarelin, 1–3×/day same timing. forum
Sermorelin + hexarelin: Older GHRH fragment pairing still discussed as a dual-path pulse stack. forum
Why GHRH + GHRP (not two GHRPs): Distinct receptors (GHRH-R vs GHS-R1a); literature and forums treat this as synergistic. Stacking hexarelin + GHRP-2 + GHRP-6 is widely called redundant (same receptor class) and spillover-additive. trialforum
Rotate / switch to Ipamorelin: Common when users want longer runs with less cortisol/prolactin or when hexarelin desensitization dominates. forum
Vs pure Ipamorelin stacks: Many long-term “GH optimization” logs prefer CJC no-DAC + Ipamorelin for selectivity; hexarelin reserved for shorter high-amplitude blocks. forum
BPC-157 / TB-500 (“Wolverine”) + GH axis: Occasional heal + secretagogue lifestyle stacks—outcomes confounded; no requirement to combine. forum
MK-677 (ibutamoren) overlap caution: Both hit GH secretagogue pathways; some advanced logs layer oral MK with injectables, others avoid stacking two strong GHS approaches due to side-effect load (hunger, water, insulin sensitivity talk)—not a hexarelin-specific trial protocol. forum
Avoid multi-GHRP blasts: Hexarelin + GHRP-2 and/or GHRP-6 same day often discouraged as little extra mechanism with more PRL/cortisol risk. forum
HGH comparison framing: Forums contrast pulsed secretagogue stacks vs exogenous rHGH for cost, detection lore, and physiologic pulse vs flat elevation—not a clinical substitution protocol. forum

Access talk 5

2026 shelves: RUO vials and “strongest GHRP” marketing. Identity/fill risk is the same gray-market problem as other GHRPs. forum
Not on the July 2026 PCAC seven. trial
No 503A/503B compounding pathway in 2026 trackers — hexarelin is a research-chem GHRP, not a clinic bulk like sermorelin. trial
Not a heart drug: CD36 / cardioprotection papers are preclinical interest — not a compounding indication and not a self-experiment protocol. animal
WADA: GH secretagogues / GHRPs remain prohibited. trial

Labs people mention 5

IGF-1 is a weak hex scoreboard. Rahim’s chronic SC schedule found IGF-I largely unchanged even while GH pulses were still happening — 2026 threads that “check if hex works” with a single morning IGF-1 often read a nothing-burger. trialforum
If you lab at all: prolactin and (when someone is chasing mood/sleep) a cortisol-ish check get more hex-specific chatter than IGF-1. forum
Glucose: class GH-axis insulin-sensitivity talk, especially stacked with MK-677 or rGH. forum
If IGF-1 explodes: look for DAC-CJC, MK-677, or somatropin in the same month before crediting 100 mcg hex. forum
Don’t titrate to 200–300 ng/mL on hex alone — that sweet-spot lore is rGH/DAC talk. forum

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 8

Watch for 19

Cortisol / ACTH: Dose-related rises at GH-effective doses in human IV studies; community brands hexarelin “dirtier” than Ipamorelin on HPA axis spillover. trialforum
Prolactin: Documented dose-dependent rises; forum concerns about libido, mood, or gynecomastia risk when PRL is elevated—monitor talk is common though not trial-mandated for gray-market use. trialforum
Water retention & edema-like feel: Fluid retention, puffiness, joint tightness reported in GHRP/GH-axis user logs. forum
Numbness / tingling: Extremity tingling or carpal-tunnel-like sensations discussed (GH-related lore). forum
Appetite / hunger: Increased hunger for some; generally framed as less extreme than GHRP-6. forum
Flush / headache / fatigue: Facial flushing, brief fatigue, headache after injections appear in user reports. forum
Injection site: Redness, sting, irritation, or lipodystrophy risk with repeated SC sites. forum
Sleep disruption (subset): Night dosing may worsen sleep for users sensitive to cortisol spillover—individual. forum
IGF-I / metabolic honesty: Chronic SC research schedule did not reliably raise IGF-I; glucose/insulin sensitivity concerns are general GH-axis cautions discussed in secretagogue communities. trialforum
Cardiac research ≠ safe self-use: Cardioprotective animal data and CD36 interest do not establish safety or benefit of unsupervised use; cardiovascular disease self-treatment is out of scope for research-chem forums. animalforum
Source quality: Mislabeling, underdosing, and impure gray-market vials are repeatedly flagged risks. forum
Not approved / research status: Not an FDA-approved therapy for body composition or anti-aging; forum protocols are not safety-validated clinical standards. forum
Drug / hormone interactions (discussion only): Stacking with other GHS, thyroid, or high-androgen cycles may compound side-effect monitoring complexity—community caution, not formal interaction labeling. forum
Cortisol / prolactin spillover: Still the “dirty GHRP” watch-for vs ipamorelin — sleep, libido, wired-tired. forum
Desensitization: Pulse fade by weeks 4–8 is expected in 2026 cycling talk; escalating mcg is the usual mistake. forum
Water / carpal / glucose: Same GH-axis triad when hex is stacked or run multi-daily. forum
Cardiac research ≠ gym safety: CD36 interest does not cancel spillover or gray-vial risk. forum
Desensitization / tachyphylaxis: Progressive attenuation of GH response with chronic/frequent use; human BID SC data support partial reversible blunting over weeks–months. Key practical downside vs selective GHRPs. trial
Population gaps: Much classic PK/PD is healthy adult men; elderly, short-stature pediatric, and disease-state papers exist but do not translate into consumer dosing rules. trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

What people say 11

Doses people talk about 17

How it may feel 10

Around the dose 6

Cycles people discuss 9

Timing 10

More on what it is 6

Stacks 9

Access talk 5

Labs people mention 5

Storage notes 2

Related 8

Watch for 19

Timing context & sources